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Introduction: Hepatic Encephalopathy is a syndrome observed in patients with liver cirrhosis. Various treatment 
modalities are in use for the treatment of Porto Systemic Encephalopathy (PSE). Our study aimed to compare the 
efficacy of Rifaximin plus Lactulose vs. Lactulose alone in the treatment of Hepatic Encephalopathy in the local 
population. 
Material and Methods: The study was conducted at a tertiary care hospital recruiting decompensated chronic 
liver disease (DCLD) patients with PSE. Using simple random sampling, patients were divided into two groups 
(A & B). Patients in group A received Lactulose plus Rifaximin while group B received Lactulose alone. Efficacy 
of treatment was assessed as the return of the conscious level to pre-encephalopathy state as per clinical 
examination within 1 week after initiation of the treatment. 
Results: A total of 124 patients were included in the study with each group (A & B) containing 62 patients. 
Frequency and percentage of efficacy among group A (Rifaximin plus Lactulose) versus group B (Lactulose alone) 
in treating Hepatic encephalopathy was 45 (72.6%) and 32 (51.6%) respectively.  
Conclusion: The study concluded that there is a significant difference in proportions of patients showing 
complete recovery from Hepatic encephalopathy treated with Lactulose plus Rifaximin as compared to Lactulose 
alone.  
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Liver cirrhosis is the final common pathological 
pathway of liver damage arising from a wide variety 
of chronic liver diseases. The aetiology of cirrhosis 
varies geographically with Alcoholic liver disease, 
Chronic Hepatitis C Virus (HCV) infection, and non-
alcoholic fatty lives disease (NAFLD) being the most 
common causes in western countries, whereas chronic 
hepatitis B and C are the primary cause of liver 
cirrhosis in the Asia-Pacific region.1,2 
Liver cirrhosis is associated with a number of 
complications that can even lead to mortality but the 
most common complication is portosystemic 
encephalopathy that results in significant mortality.3 
Hepatic encephalopathy is defined as a spectrum of 
neuropsychiatric abnormalities in patients with liver 
dysfunction, after exclusion of other known brain 
diseases. The development of hepatic encephalopathy 
is explained, to some extent, by the effect of neurotoxic 
substances, which occurs in the setting of cirrhosis and 
portal hypertension.4 The development of hepatic 
encephalopathy negatively impacts patient survival. 
The occurrence of encephalopathy leads to 
hospitalization is associated with a survival 
probability of 42% at 1-year o and 23% at 3 years. 
Hepatic encephalopathy is also the most common, 
possibly preventable, cause for readmission.5 
Ammonia produced in the gut mainly by the colonic 
bacteria is the most important neurotoxic substance 
involved in the pathogenesis of PSE.4 Lactulose 
decreases the ammonia levels by increasing its release 
from the gut by decreasing the transit time of gut, 
decreases production and increased consumption of 
ammonia in the gut by acting on various groups of 
colonic bacteria.6 
Rifaximin also helps PSE by having a bactericidal 
effect on ammonia producing gut flora.7 The rationale 
of this study was to assess the efficacy of lactulose 
alone vs. in combination with Rifaximin for the 
treatment of PSE. 
 
Materials and Methods 
 
After approval from the ethical review committee, a 
randomized controlled trial was conducted in the 
Gastroenterology Department of Holy Family Hospital 
Rawalpindi for 6 months from 16th of March 2019 to 
15th of September 2019 in patients of both sex groups 
with ages in the range of 20-70 years suffering from 
hepatic encephalopathy. Patients with liver cirrhosis 
who presented with symptoms ranging from 
irritability and confused state to coma as per clinical 
examination (>6 hours) were labeled to have hepatic 
encephalopathy and its grade (I-IV) was categorized 
on West Heaven Criteria of hepatic encephalopathy.8 
Patients with renal impairment (serum creatinine>1.5 
mg/dl), or having space-occupying lesion of the liver 
(on abdominal ultrasound),  serum sodium<120 
mmol/l as per investigations, patients allergic to 
Rifaximin and patients with stroke (on CT scan), CNS 
infection, history of fits or anti-psychiatric medications 
were excluded. 
Written informed consent was taken from the first 
relatives of the patients. After a brief history and 
confirmation of diagnosis, patients were stratified into 
either group A or B. Group A patients received 
Lactulose plus Rifaximin while group B received 
Lactulose alone. The enrollment in study groups was 
made through randomization through the lottery 
method. 
Group A received Tab Rifaximin 550 mg twice a day 
and Lactulose 30 ml thrice a day so that patients pass 
at least 2 semi-soft stools per day. Patients in group B 
were treated with lactulose 30ml three times a day. 
Patients were managed and monitored as per standard 
treatment protocols for the management of hepatic 
encephalopathy. All relevant investigations were 
carried out to classify patients for the CTP score. All 
the patients had received medication from the same 
pharmaceutical company to eliminate bias and 
confounding variables were controlled by exclusion. 
The primary outcome measure was a complete 
reversal of the conscious level to pre- encephalopathy 
state. Patients were given treatment until complete 
recovery or a maximum of seven days of treatment. 
Patients not responding to treatment after seven days 
were considered as treatment failures. 
All the data was noted and recorded on Performa 
which contained patients’ demographic and clinical 
information. The grade of the hepatic encephalopathy 
and efficacy of the treatment was presented as 
frequency and percentage. Chi-square test was applied 
for comparison of the efficacy of the treatment 
between the two groups taking a p-value of ≤0.05 as 
statistically significant. 




A total of 124 patients were included according to the 
inclusion criteria of the study. The mean age of the 
population was 45.18 + 15.20 years. There were 69 
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(55.6%) male and 55 (44.4%) female patients. Patients 
were divided into two groups. Group A patients 
received Lactulose plus Rifaximin while group B 
received Lactulose alone.  
Grades of hepatic encephalopathy on presentation 
assessed in terms of frequency and percentage.  46 
(37.1%) patients were presented with grade IV hepatic 
encephalopathy and 43 (34.7%) patients with grade III 
hepatic encephalopathy. This is illustrated in Table 1. 
 
Table 1: Frequency & percentage of Grade of Hepatic 
Encephalopathy among both groups at the time of 
admission 










Grade I 7 3 10 
11.3% 4.8% 8.1% 
Grade II 12 13 25 
19.4% 21.0% 20.2% 
Grade III 21 22 43 

















The purpose of the study was to compare the efficacy 
of Rifaximin plus Lactulose versus Lactulose alone in 
treating patients with hepatic encephalopathy. The 
frequency and percentage of efficacy with Rifaximin 
plus Lactulose vs Lactulose alone was 45 (72.6%) and 
32 (51.6%) respectively, as shown in Table 2. The chi-
square test showed a significant difference between 
the two groups (P=0.016). Therefore we recommend 
that a combination of Lactulose and Rifaximin as 
compared to lactulose alone is a much better treatment 
modality for patients with hepatic encephalopathy. 
 
Table 2: Comparison of efficacy between two 
groups(A and B) 





Efficacy Yes 45 32 77 
72.6% 51.6% 62.1% 
No 17 30 47 
27.4% 48.4% 37.9% 
Total 62 62 124 
Effect modifiers on treatment like age, gender, and 
grade of hepatic encephalopathy were compared with 
the efficacy of the two groups that revealed a 
statistically significant efficacy of Lactulose and 
Rifaximin in the age group 20-40, male patients and 
hepatic encephalopathy grade. This is shown in Tables 
3, 4, and 5. 
 
Table 3: Effect modifier like Age stratification with 
















Yes 23 10 33 0.012 
 79.3% 45.5% 64.7 
No 6 12 18 





Yes 22 22 44 0.311 
66.7% 55.0% 60.3% 
No 11 18 29 
33.3% 45.0% 39.7% 
 
Table 4: Effect modifier like Gender stratification 














Yes 22 21 43 0.058 
 75.9% 52.5% 62.3% 
No 7 19 26 




Yes 23 11 34 0.308 
69.7% 50.0% 61.8% 
No 10 11 21 












342                                                                             Journal of Rawalpindi Medical College (JRMC); 2020; 24(4): 339-343  
Table 5: Effect modifier like Grade of Hepatic Encephalopathy stratification with the comparison of Efficacy 




Efficacy Two Groups Total P-Value 





6 2 8 0.490 
 85.7% 66.7% 80.0% 
No 1 1 2 





9 6 14 0.302 
 66.7% 42.2% 56.0% 
No 4 7 11 
33.3% 53.8% 44.0% 
Grade III Yes 15 10 25 0.084 
  71.4% 45.5% 58.1% 
No 6 12 18 
28.6% 54.5% 41.9% 
Grade IV Yes 16 14 30 0.306 
 72.7% 58.3% 65.2% 
No 6 10 16 




Hepatic encephalopathy is a serious but potentially 
reversible disorder with a wide spectrum of 
neuropsychiatric abnormalities and motor 
disturbances that range from mild alteration of 
cognitive and motor function to coma and death. It is a 
challenging complication of advanced liver disease 
and is estimated to occur in 30 to 45% of patients with 
liver cirrhosis and 10–50% of patients with Trans-
jugular intrahepatic Porto-systemic shunts.10 The 
survival probability is 42 % at 1 year of follow-up and 
23% at 3 years in patients with cirrhosis with the first 
episode of hepatic encephalopathy.11 The primary 
treatment is the identification and treatment of the 
precipitating factors. The majority of the drugs used in 
the treatment of hepatic encephalopathy are primarily 
directed at the reduction or elimination of the 
increased neurotoxic ammonia levels. Lactulose, a 
non-absorbable disaccharide, remains the mainstay 
treatment for PSE. Despite the widespread use of 
Lactulose, evidence supporting its efficacy for the 
treatment of hepatic encephalopathy is limited. A 
systematic review of the literature found lactulose to 
be more effective than placebo in improving 
encephalopathy, but with no effect on mortality.12  
However, when only the highest-quality studies were 
included, no significant effect on the improvement of 
hepatic encephalopathy was seen with Lactulose 
therapy. 
Rifaximin, a semisynthetic derivative of Rifamycin, is 
minimally absorbed. It has broad-spectrum in vitro 
activity against gram-positive and gram-negative 
aerobic and anaerobic enteric bacteria and has a low 
risk of inducing bacterial resistance. No dosage 
adjustments are necessary for patients with liver 
dysfunction or renal insufficiency.13 With minimal 
systemic bioavailability, Rifaximin may be more 
conducive to long-term use than other, more 
bioavailable antibiotics with detrimental side effects. It 
has been proven to prevent the episode of hepatic 
encephalopathy and decrease the risk of 
hospitalization. In randomized studies, Rifaximin was 
more effective than non-absorbable disaccharides and 
had efficacy that was equivalent to or greater than that 
of other antibiotics used in the treatment of acute 
hepatic encephalopathy.12 In a recent meta-analysis, 
Rifaximin is as effective as other conventional oral 
agents for the treatment of hepatic encephalopathy 
with a better safety profile. There is a paucity of data 
on the evaluation of a combination of Rifaximin plus 
Lactulose in the treatment of hepatic encephalopathy.13 
In our study, the mean age (years) was 45.18 + 15.20. 
In this study, the majority of the patients 46 (37.1%) 
were presented with grade IV of hepatic 
encephalopathy, following by 43 (34.7%) patients of 
grade III hepatic encephalopathy. These results are 
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quite comparable with previous studies.9 In our study, 
the percentage of efficacy among Rifaximin plus 
Lactulose vs. Lactulose alone for the treatment of 
hepatic encephalopathy was 72.6% and 51.6% 
respectively. Likewise, Sharma et al in 2013 conducted 
a study and found that the efficacy of Lactulose plus 
Rifaximin was 76% vs. Lactulose alone 44% showed 
complete reversal of hepatic encephalopathy.9 In light 
of our results and comparison with previous studies 
management plan of hepatic encephalopathy should 
consist of Lactulose plus Rifaximin rather than 
Lactulose alone if there are no contraindications for a 




The study concluded that there is a significant 
difference in proportions of patients getting complete 
recovery from hepatic encephalopathy treated with 
Lactulose plus Rifaximin as compared to Lactulose 
alone. The combination is more efficacious than 
Lactulose alone. However, further studies at different 
centers can be conducted to reach concrete evidence of 
optimizing the better treatment modality for the 
patients suffering from Hepatic Encephalopathy and 
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